Objective: To investigate the influence of thoracoscopic surgery after neoadjuvant chemotherapy on serum levels of cytokeratin 19 fragment antigen (CYFRA21-1) and neuron-specific enolase (NSE) in patients with newly diagnosed stage Ⅲa-N2 non-small cell lung cancer (NSCLC). Methods: 82 cases of patients with newly diagnosed stage Ⅲa-N2 NSCLC were randomly divided into observation group (n=41) and control group (n=41). The observation group underwent thoracoscopic surgery after preoperative neoadjuvant chemotherapy, the control group underwent thoracoscopic surgery. The surgical conditions and clinical outcomes of the two groups were compared. Serum CYFRA21-1 and NSE levels were measured before and after treatment. Results: There was no significant difference in the number of lymph node dissections, operation time and postoperative complications between the two groups (P>0.05),the surgical resection rate in the observation group was significantly higher than that in the control group (95.12% vs 78.05%, P<0.05), and the amount of blood loss in the observation group was significantly shorter than that in the control group (P<0.05). The serum levels of CYFRA21-1 and NSE in the observation group after treatment were significantly lower than those in the control group (P<0.05). There was no significant difference in 1-year recurrence metastasis rate (20.59% vs 33.33%,P>0.05) and survival rates between the two groups (88.24% vs 76.67%, P>0.05),while the 3-and 5-year recurrence metastasis rates in the observation group were significantly lower than those in the control group (35.29% vs 56.67%,58.82% vs 86.67%;P<0.05),the 3-and 5-year survival rates in the observation group were significantly higher than those in the control group (67.65% vs 53.33%,41.18% vs 20.00%;P<0.05). Conclusion: Thoracoscopic surgery after neoadjuvant chemotherapy can significantly improve the resection rate and therapeutic effect without increase of complications,which can reduce serum CYFRA21-1, NSE levels. |
[1] 沈月,夏建洪,王珂,等.培美曲塞+顺铂方案同步放疗治疗局部晚期非鳞非小细胞肺癌的临床观察[J].东南大学学报(医学版),2017,36(6):912-915.
[2] 叶永强,王刚,谢宝龙,等.Ⅲa-N2期非小细胞肺癌新辅助化疗后胸腔镜手术与开胸手术的比较[J].广东医学,2017,38(23):3603-3605.
[3] 高洋,张启知,凌建华,等.非小细胞肺癌患者血清CYfra21-1、CEA、NSE手术前后的水平变化及意义[J].检验医学与临床,2018,15(2):213-216.
[4] 李健,郑琳,戚永超,等.完全与杂交式胸腔镜肺叶切除治疗早期非小细胞肺癌的疗效比较[J].现代医学, 2017,45(2):234-238.
[5] MURAKAWA T,ICHINOSE J,HINO H,et al.Long-term outcomes of open and video-assisted thoracoscopic lung lobeetomy for the treatment of early stage non-small cell lung cancer are similar:a propensity-matched study[J].World J Surg,2015,39(5):1084-1091.
[6] 龚玉芳,刘峰,杨志胤,等.新辅助化疗前后非小细胞肺癌患者血清CA125、CEA及CYFRA21-1的变化及预后分析[J].中国医药导报,2017(11):91-94.
[7] 牟志民,毛广显,谢远财,等.ⅢA期非小细胞肺癌患者新辅助化疗后胸腔镜肺叶切除效果[J].安徽医学,2015,36(4):410-412.
[8] KAMEL M K,NASAR A,STILES B M,et al.Video-assisted thoracoscopic lobectomy is the preferred approach following induction chemotherapy[J].J Laparoendosc Adv Surg Tech A,2017,27(5):495-500.
[9] 张梁,武绍远.新辅助化疗后胸腔镜肺叶切除治疗Ⅲ期非小细胞肺癌的疗效分析[J].实用癌症杂志,2016,31(12):1993-1995.
[10] 卢兴兵,李勤,石佳,等.多种血清肿瘤标志物联合检测诊断非小细胞肺癌的临床价值[J].现代医学,2017,45(10):1417-1421.
[11] 于亚波,丛占杰.老年非小细胞肺癌ECOG评分、CYFRA21-1、NSE与外科手术预后关系[J].临床与实验病理学杂志,2017,33(7):806-809.
[12] EDELMAN M J,TANM T,FIDLER M J,et al.Randomized, double-blind, placebo-controlled, multicenter phase Ⅱ study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer[J].J Clin Oncol,2015,33(2):189-194.
[13] CHEN F,WANG X Y,HAN X H,et al.Diagnostic value of CYFRA21-1,SCC and CEA for differentiation of early-stage NSCLC from benignlung disease[J].Int J Clin Exp Med,2015,8(7):11295-11300.
[14] 潘洁,毕怡,任玉欣,等.血清细胞角蛋白19片段、肿瘤相关糖链抗原、血管内皮生长因子联合检测诊断非小细胞肺癌的价值[J].现代中西医结合杂志,2015,24(12):1340-1341,1346.
[15] DUAN X,CUI Y,LI H,et al.High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA21-1 indicate poor prognosis in patients with pathological stage I nonsmall cell lung cancer[J].Indian J Cancer,2015,52(3):158-163. |